ASPECTOS ETICOS DE LA INVESTIGACION CON CONTROL PLACEBO
Columnista Experta de SIIC William Carpenter
en colaboración con
Robert J. Levine, M.D. , Yale University School of Medicine, Departments of Medicine and Pharmacology, New Haven, CT; Paul S. Appelbaum, M.D. , University of Massachusetts Medical School, Department of Psychiatry, Worcester, MA
Primera edición en siicsalud:
4 de octubre, 2005
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/71327
Especialidad principal:
Bioética
Especialidades relacionadas:
Farmacología,Medicina Farmacéutica,Medicina Interna,
Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations, Drugs 65(65):1113-38, 2005
Hong LE, Wonodi I, Avila MT, Buchanan RW, McMahon RP, Mitchell BD, Stine OC, Carpenter WT Jr, Thaker GK. Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia, Am J Med Genet B Neuropsychiatr Genet 136(136):8-11, 2005
Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus, Am J Psychiatry 162(162):441-9, 2005
Carpenter WT Jr, Koenig JI, Bilbe G, Bischoff S. At issue: A model for academic/industry collaboration, Schizophr Bull 30(30):997-1004, 2004
Carpenter WT Jr. Clinical constructs and therapeutic discovery, Schizophr Res 72(72):69-73, 2004
Koenig JI, Carpenter WT. Cannabis and psychosis, Br J Psychiatry 185:352, 2004
William Carpenter
